Sign-up for our newsletter

Publication

Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice

Authors Ira J. Goldberg, Aaron Isaacs, Ephraim Sehayek, Jan L. Breslow, Li-Shin Huang Submitted By Ira Goldberg on 3/5/2004 Status Published Journal Atherosclerosis Year 2004 Date Published 1/1/2004 Volume : Pages 172 : 47 - 53 PubMed Reference 14709356 Abstract During the past decade a number of investigators have attempted to develop mouse models of diabetic macrovascular disease. Hyperglycemia might increase vascular damage because it increases oxidant stress. For this reason we studied animals that were deficient in HDL; HDL is widely believed to protect against oxidant stress. An inbred line of mice doubly deficient in LDL receptor and apoAI was made diabetic with streptozotocin (STZ); control mice had an average glucose of 7.2 ± 2 mmol/L and STZ-treated mice had an average glucose of 19.4 ± 6.5 mmol/L. The animals were fed a high cholesterol but low fat diet leading to plasma cholesterol levels of 9.4 ± 1.6 mmol/L in control animals and 10.1 ± 1.8 mmol/L in STZ-treated mice. The control and STZ-treated animals had similar plasma lipoprotein profiles. Atherosclerosis assessed at 23 weeks averaged 38154 µm2 in control and 32962 µm2 in STZ-treated mice. Therefore STZ-induced diabetes does not alter plasma lipoproteins or atherosclerosis in HDL deficient mice.

Complications
All ComplicationsBioinformatics BoneCardiomyopathy CardiovascularGastro-Intestinal (GI) NephropathyNeuropathy & Neurocognition Pediatric Endocrinology Retinopathy UropathyWound Healing

Genes
Symbol Description Apoa1 apolipoprotein A-I Ldlr low density lipoprotein receptor